Talazoparib is a PARP inhibitor used for the treatment of specific solid tumors such as breast cancer.The following introduces its dosage and administration, efficacy, and precautions.

1.Dosage and administration

1.Recommended dose

The recommended dose is 1 mg orally once daily.

It can be taken with food or on an empty stomach, and it is recommended to take the medication at a fixed time each day.

2.Dose adjustment

If adverse reactions occur, doctors may pause the medication, reduce the dose, or discontinue treatment.

Patients with moderate renal impairment need a dose reduction to 0.75 mg daily.

Patients with severe renal impairment need a dose reduction to 0.5 mg daily.

3.Missed dose management

If a dose is missed, take it as soon as you remember.

If it is already close to the next scheduled dose, skip the missed dose and take it according to the original plan.

Do not take a double dose at one time.

2.Efficacy

1.Applicable population

It is used for patients with HER2-negative locally advanced or metastatic breast cancer carrying germline BRCA mutations.

It can also be used for other specific solid tumors, based on doctor evaluation.

2.Mechanism of action

It interferes with tumor cell DNA repair by inhibiting the PARP enzyme.

It has a selective killing effect on BRCA-mutated tumor cells.

3.Efficacy characteristics

It can prolong progression-free survival and improve the objective response rate.

Efficacy varies depending on tumor type, gene mutation status, and individual differences.

3.Precautions

1.Myelosuppression

It can cause anemia, neutropenia, and thrombocytopenia.

Blood tests should be performed regularly before and during treatment.

If severe myelosuppression occurs, the medication should be paused or the dose adjusted.

2.Anemia and fatigue

Anemia can present as fatigue, dizziness, and shortness of breath.

Fatigue is a common adverse reaction, and rest should be arranged reasonably with moderate activity.

If symptoms are severe, inform the doctor to investigate the cause and manage it.

3.Drug interactions

Talazoparib is mainly metabolized by CYP3A4.

Avoid combination with strong CYP3A4 inhibitors or inducers.

If concomitant use is necessary, the doctor may adjust the dose and strengthen monitoring.

4.Special populations

It is contraindicated in pregnant women and may cause harm to the fetus.

Breastfeeding women should stop breastfeeding during treatment.

Women of childbearing potential should use effective contraception during treatment and after discontinuation.